Skip to main content
Premium Trial:

Request an Annual Quote

Leena Das-Young

Guardant Health has appointed Leena Das-Young to serve as general manager of its LUNAR program. In her new role, Das-Young will oversee all work applying Guardant Health's technology and database of more than 70,000 clinical Guardant360 assay results, toward new applications in early-stage cancer, such as residual detection, recurrence monitoring, and early detection.

Prior to joining Guardant, Das-Young was vice president and head of the late phase strategy development group at Pfizer's oncology group, where she was responsible for a portfolio of oncology programs including Ibrance, Xalkori, Besponsa, Sutent, lorlatinib, and others. Prior to her roles in product development, she served in various commercial roles responsible for several successful launches at both Pfizer and Bayer.  She holds BS and Doctor of Pharmacy degrees from Purdue University.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.